GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » Gross Margin %
中文

Pacira BioSciences (Pacira BioSciences) Gross Margin % : 73.69% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Pacira BioSciences's Gross Profit for the three months ended in Dec. 2023 was $133.6 Mil. Pacira BioSciences's Revenue for the three months ended in Dec. 2023 was $181.2 Mil. Therefore, Pacira BioSciences's Gross Margin % for the quarter that ended in Dec. 2023 was 73.69%.


The historical rank and industry rank for Pacira BioSciences's Gross Margin % or its related term are showing as below:

PCRX' s Gross Margin % Range Over the Past 10 Years
Min: 60.16   Med: 71.9   Max: 74.65
Current: 72.64


During the past 13 years, the highest Gross Margin % of Pacira BioSciences was 74.65%. The lowest was 60.16%. And the median was 71.90%.

PCRX's Gross Margin % is ranked better than
86.16% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.765 vs PCRX: 72.64

Pacira BioSciences had a gross margin of 73.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Pacira BioSciences was -0.80% per year.


Pacira BioSciences Gross Margin % Historical Data

The historical data trend for Pacira BioSciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Gross Margin % Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.65 72.69 74.10 70.11 72.64

Pacira BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.99 69.43 71.55 75.75 73.69

Competitive Comparison of Pacira BioSciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Gross Margin % falls into.



Pacira BioSciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Pacira BioSciences's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=490.3 / 674.978
=(Revenue - Cost of Goods Sold) / Revenue
=(674.978 - 184.669) / 674.978
=72.64 %

Pacira BioSciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=133.6 / 181.244
=(Revenue - Cost of Goods Sold) / Revenue
=(181.244 - 47.692) / 181.244
=73.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Pacira BioSciences  (NAS:PCRX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Pacira BioSciences had a gross margin of 73.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Pacira BioSciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (Pacira BioSciences) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
Executives
Marcelo Bigal director C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Abraham Ceesay director C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Roy Winston officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Lauren Bullaro Riker officer: Executive Director, Accounting C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Kristen Marie Williams officer: CAO and General Counsel C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Mark A. Kronenfeld director C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Daryl Gaugler officer: Chief Operating Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Reinhart Charles A. Iii officer: Chief Financial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Ellis Ronald J. Jr. officer: Chief Strategy Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Max Reinhardt officer: President C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
David M Stack director, officer: President and CEO THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Dennis Mcloughlin officer: Chief Commercial Officer C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Jonathan Slonin officer: Chief Clinical Officer C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054